Orphan drugs
Why in News?
On 29 September 2026, the United States announced a 0% tariff exemption for selected specialty medicines imported from India and other countries, despite imposing 100% duties on certain pharmaceutical products.
Definition and Prevalence
- Core Meaning: An orphan drug is a pharmaceutical agent developed specifically to treat, prevent, or diagnose rare medical conditions (orphan diseases). They are dubbed "orphan" because the pharmaceutical industry has historically lacked the financial incentive to develop them for such small patient pools without government aid.
- Geographic Variations in Definition: Rarity is defined differently by region:
- United States: Affects fewer than 200,000 people nationwide.
- European Union: Affects no more than 5 in 10,000 people.
- Japan: Affects fewer than 50,000 patients.
- India: Targets a patient population of fewer than 500,000.
- The Treatment Gap: There are more than 7,000 recognized rare diseases globally. Despite major progress, fewer than 5% of these conditions currently have an FDA-approved treatment.
Government Incentives for Development
To overcome low market demand, global legislation—pioneered by the US Orphan Drug Act of 1983—provides several key benefits to developers:
To overcome low market demand, global legislation—pioneered by the US Orphan Drug Act of 1983—provides several key benefits to developers:
- Market Exclusivity: A guaranteed monopoly period (7 years in the US, 10 years in the EU) during which no generic alternative can be approved.
- Financial Rebates: Tax credits covering up to 25% to 50% of qualified clinical trial costs.
- Fee Waivers: Exemption from multi-million-dollar regulatory application user fees (like PDUFA fees in the US).
- Expedited Pathways: Fast-track reviews and dedicated protocol assistance from regulatory experts to shorten clinical trial timelines.
Disease Categories and Key Examples
Orphan drugs broadly target life-threatening genetic, metabolic, or rare cancerous disorders:
Orphan drugs broadly target life-threatening genetic, metabolic, or rare cancerous disorders:
- Genetic Disorders: Ivacaftor (for Cystic Fibrosis) and Nusinersen (for Spinal Muscular Atrophy).
- Rare Cancers: Revlimid (used for late-stage non-Hodgkin's lymphoma and multiple myeloma).
- Blood Disorders: Coagulation factor IX (for Hemophilia B) and Alexion/Eculizumab (for paroxysmal nocturnal hemoglobinuria).
- Astronomical Prices: Because the consumer pool is small, companies price these drugs extremely high to recoup costs, passing the financial strain onto families and public healthcare budgets.
- Scientific Obstacles: Clinical trials are tough to design and execute due to the very small, geographically scattered patient populations available for testing.
